Summary
Petrelintide targets amylin, a different hormone pathway from GLP medicines.
What researchers tested
In Germany, 48 adults with overweight or obesity were assigned weekly petrelintide or placebo for 16 weeks. Safety was the main question; weight was secondary. Results are observed weight changes, not placebo-adjusted differences.
Percent of starting weight; sequential cohorts, not placebo-adjusted
Original visual based on the study.
| Group or measure | Result |
|---|---|
| 2.4 mg target | 4.8% |
| 4.8 mg target | 8.6% |
| 9.0 mg target | 8.3% |
| Placebo | 1.7% |
The trade-offs
Three of 36 petrelintide participants stopped: two for personal reasons and one because of digestive symptoms. No serious or severe treatment-emergent adverse events were reported. Nausea occurred.
What it means
This cannot establish long-term safety or superiority over other medicines. All participants were White and most were men.
Zealand Pharma funded the research and manuscript.
Sources
Olsen and colleagues, Diabetes, Obesity and Metabolism, 2026